Proteomics of Human Hepatoma Huh-7 Cells Treated by Three Multi-RTK Inhibitors

ABSTRACT: Sorafenib, lenvatinib and regorafenib, the multi-RTK inhibitors with potent anti-angiogenesis effects, are currently therapeutic drugs generally recommended for the patients with advanced hepatocellular carcinoma (HCC). To date, however, there have been no published studies on the mechanism underling differential effects of the three drugs on HCC cell proliferation, and the proteomic analysis in HCC cell lines treated by regorafenib or lenvatinib.The present project for the first time performed a direct comparison of their pharmacological interventions for influencing whole cell proteomics using tandem mass tag-based peptide-labeling technique.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Hepatocyte

SUBMITTER: Dezhi Kong  

LAB HEAD: Dezhi Kong

PROVIDER: PXD034073 | Pride | 2022-10-13

REPOSITORIES: pride